While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

Christina Gentry, DVM, DACVM, shared a key dermatology takeaway from her co-presented CE session on concurrent disease.

The global Canine Urolithiasis Treatment Market is positioned for sustained expansion over the next decade as pet owners and ...

From time to time, we can be hypochondriacs—we think we have a medical issue and it turns out to be nothing at all. But every ...

The global Canine Urolithiasis Treatment Market is positioned for sustained expansion over the next decade as pet owners and veterinary professionals ...

Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...